{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:16:14Z","timestamp":1790270174741,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007208","name":"Vanderbilt-Ingram Cancer Center","doi-asserted-by":"publisher","award":["P30 CA68485"],"award-info":[{"award-number":["P30 CA68485"]}],"id":[{"id":"10.13039\/100007208","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vanderbilt Digestive Disease Research Center","award":["DK058404"],"award-info":[{"award-number":["DK058404"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R21AI121626"],"award-info":[{"award-number":["5R21AI121626"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002326","name":"Science Foundation","doi-asserted-by":"publisher","award":["CBET-1554623"],"award-info":[{"award-number":["CBET-1554623"]}],"id":[{"id":"10.13039\/100002326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vanderbilt University Discovery"},{"name":"American Cancer Society Institutional Research","award":["IRG-58-009-56"],"award-info":[{"award-number":["IRG-58-009-56"]}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201406245022"],"award-info":[{"award-number":["201406245022"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Veteran's Administration Merit","award":["BX001444 (SJ)"],"award-info":[{"award-number":["BX001444 (SJ)"]}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen\u00ae","doi-asserted-by":"crossref","award":["PDF18377947"],"award-info":[{"award-number":["PDF18377947"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stand Up To Cancer Innovative Research","award":["SU2C-AACR-IRG 20-17"],"award-info":[{"award-number":["SU2C-AACR-IRG 20-17"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.biomaterials.2018.07.052","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T05:34:11Z","timestamp":1532928851000},"page":"82-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"special_numbering":"C","title":["Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines"],"prefix":"10.1016","volume":"182","author":[{"given":"Feng","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessalyn J.","family":"Baljon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Sevimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlo","family":"Gilchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"334","key":"10.1016\/j.biomaterials.2018.07.052_bib1","doi-asserted-by":"crossref","first-page":"334ps9","DOI":"10.1126\/scitranslmed.aaf0685","article-title":"The Human Vaccines Project: a roadmap for cancer vaccine development","volume":"8","author":"Romero","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"6280","key":"10.1016\/j.biomaterials.2018.07.052_bib2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.biomaterials.2018.07.052_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"32","key":"10.1016\/j.biomaterials.2018.07.052_bib4","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.07.052_bib5","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nm.3161","article-title":"Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells","volume":"19","author":"Robbins","year":"2013","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.biomaterials.2018.07.052_bib6","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.biomaterials.2018.07.052_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2018.07.052_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2015.12.001","article-title":"Mutanome directed cancer immunotherapy","volume":"39","author":"Vormehr","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"9","key":"10.1016\/j.biomaterials.2018.07.052_bib9","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1172\/JCI80008","article-title":"Tumor neoantigens: building a framework for personalized cancer immunotherapy","volume":"125","author":"Gubin","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"6382","key":"10.1016\/j.biomaterials.2018.07.052_bib10","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"6230","key":"10.1016\/j.biomaterials.2018.07.052_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"7662","key":"10.1016\/j.biomaterials.2018.07.052_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.biomaterials.2018.07.052_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2018.07.052_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/2326-6066.CIR-13-0022","article-title":"Getting personal with neoantigen-based therapeutic cancer vaccines","volume":"1","author":"Hacohen","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.07.052_bib16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat. Rev. Canc."},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.coi.2010.04.002","article-title":"Designing CD8+ T cell vaccines: it's not rocket science (yet)","volume":"22","author":"Yewdell","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.biomaterials.2018.07.052_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: overcoming the challenges posed by immune evasion","volume":"16","author":"van der Burg","year":"2016","journal-title":"Nat. Rev. Canc."},{"issue":"4","key":"10.1016\/j.biomaterials.2018.07.052_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ejps.2011.08.016","article-title":"License to kill: formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems","volume":"45","author":"Foged","year":"2012","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.07.052_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coi.2010.01.022","article-title":"Intracellular mechanisms of antigen cross presentation in dendritic cells","volume":"22","author":"Amigorena","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"7272","key":"10.1016\/j.biomaterials.2018.07.052_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature08604","article-title":"Materials engineering for immunomodulation","volume":"462","author":"Hubbell","year":"2009","journal-title":"Nature"},{"issue":"13\u201314","key":"10.1016\/j.biomaterials.2018.07.052_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drudis.2011.04.006","article-title":"Particulate vaccines: on the quest for optimal delivery and immune response","volume":"16","author":"De Temmerman","year":"2011","journal-title":"Drug Discov. Today"},{"issue":"28","key":"10.1016\/j.biomaterials.2018.07.052_bib23","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/adma.201200446","article-title":"Engineering nano- and microparticles to tune immunity","volume":"24","author":"Moon","year":"2012","journal-title":"Adv. Mater."},{"issue":"8","key":"10.1016\/j.biomaterials.2018.07.052_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2326-6066.CIR-15-0112","article-title":"Engineering new approaches to cancer vaccines","volume":"3","author":"Mehta","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib25","article-title":"A facile approach to enhance antigen response for personalized cancer vaccination","author":"Li","year":"2018","journal-title":"Nat. Mater."},{"issue":"4","key":"10.1016\/j.biomaterials.2018.07.052_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2014.03.041","article-title":"Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8(+) T cell responses","volume":"191","author":"Keller","year":"2014","journal-title":"J. Contr. Release"},{"issue":"5","key":"10.1016\/j.biomaterials.2018.07.052_bib28","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/nn305466z","article-title":"Ph-responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides","volume":"7","author":"Wilson","year":"2013","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.biomaterials.2018.07.052_bib29","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1208\/s12248-014-9697-1","article-title":"Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles","volume":"17","author":"Wilson","year":"2014","journal-title":"AAPS J."},{"issue":"11","key":"10.1016\/j.biomaterials.2018.07.052_bib30","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1021\/acs.molpharmaceut.7b00760","article-title":"Enhanced class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide","volume":"14","author":"Morishita","year":"2017","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.biomaterials.2018.07.052_bib31","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1021\/bc100204m","article-title":"Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy","volume":"21","author":"Foster","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib32","doi-asserted-by":"crossref","DOI":"10.1021\/mp300338s","article-title":"Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate","author":"Berguig","year":"2012","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.biomaterials.2018.07.052_bib33","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1021\/acsnano.5b00491","article-title":"Endosomolytic nano-polyplex platform technology for cytosolic peptide delivery to inhibit pathological vasoconstriction","volume":"9","author":"Evans","year":"2015","journal-title":"ACS Nano"},{"issue":"291","key":"10.1016\/j.biomaterials.2018.07.052_bib34","doi-asserted-by":"crossref","first-page":"291ra95","DOI":"10.1126\/scitranslmed.aaa4549","article-title":"MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia","volume":"7","author":"Evans","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2018.07.052_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/btm2.10068","article-title":"Poly(2-propylacrylic acid)\/poly(lactic-co-glycolic acid) blend microparticles as a targeted antigen delivery system to direct either CD4(+) or CD8(+) T cell activation","volume":"2","author":"Yang","year":"2017","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.biomaterials.2018.07.052_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jconrel.2017.09.018","article-title":"Self-replicating RNA vaccine functionality modulated by fine-tuning of polyplex delivery vehicle structure","volume":"266","author":"Demoulins","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.07.052_bib37","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2015.03.029","article-title":"Feasibility of a subcutaneously administered block\/homo-mixed polyplex micelle as a Carrier for DNA vaccination in a mouse tumor model","volume":"206","author":"Cui","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2018.07.052_bib38","first-page":"59","article-title":"Poly(2-ethylacrylic acid)","volume":"11","author":"Ferrito","year":"1992","journal-title":"Macromolecular Syntheses"},{"issue":"10","key":"10.1016\/j.biomaterials.2018.07.052_bib39","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/0008-5472.CAN-06-4494","article-title":"Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process","volume":"67","author":"Preynat-Seauve","year":"2007","journal-title":"Canc. Res."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.89.13.6020","article-title":"Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens","author":"Karttunen","year":"1992","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"10","key":"10.1016\/j.biomaterials.2018.07.052_bib41","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/eji.201343324","article-title":"Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation","volume":"43","author":"Rosalia","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-4939-6445-1_25","article-title":"Eliciting epitope-specific CD8+ T cell response by immunization with microbial protein antigens formulated with alpha-galactosylceramide: theory, practice, and protocols","volume":"1494","author":"Gilchuk","year":"2017","journal-title":"Meth. Mol. Biol."},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib43","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/nprot.2006.121","article-title":"Generation of peptide-MHC class I complexes through UV-mediated ligand exchange","volume":"1","author":"Rodenko","year":"2006","journal-title":"Nat. Protoc."},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Canc. Chemother. Pharmacol."},{"issue":"50","key":"10.1016\/j.biomaterials.2018.07.052_bib45","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1016\/j.vaccine.2010.09.077","article-title":"Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation","volume":"28","author":"Hirosue","year":"2010","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.biomaterials.2018.07.052_bib46","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12195-016-0446-7","article-title":"Mechanism of enhanced cellular uptake and cytosolic retention of MK2 inhibitory peptide nano-polyplexes","volume":"9","author":"Kilchrist","year":"2016","journal-title":"Cell. Mol. Bioeng."},{"issue":"39","key":"10.1016\/j.biomaterials.2018.07.052_bib48","doi-asserted-by":"crossref","first-page":"15460","DOI":"10.1073\/pnas.0707331104","article-title":"Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation","volume":"104","author":"Obst","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.07.052_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1074-7613(00)80461-6","article-title":"The duration of antigenic stimulation determines the fate of naive and effector T cells","volume":"8","author":"Iezzi","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.biomaterials.2018.07.052_bib50","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1701568","article-title":"Cutting edge: protection by antiviral memory CD8 T cells requires rapidly produced antigen in large amounts","author":"Remakus","year":"2018","journal-title":"J. Immunol."},{"issue":"5937","key":"10.1016\/j.biomaterials.2018.07.052_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1126\/science.1172845","article-title":"IRAP identifies an endosomal compartment required for MHC class I cross-presentation","volume":"325","author":"Saveanu","year":"2009","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biomaterials.2018.07.052_bib52","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity","volume":"179","author":"Bijker","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2018.07.052_bib53","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib54","doi-asserted-by":"crossref","first-page":"15221","DOI":"10.1038\/ncomms15221","article-title":"Induction of resident memory T cells enhances the efficacy of cancer vaccine","volume":"8","author":"Nizard","year":"2017","journal-title":"Nat. Commun."},{"issue":"204","key":"10.1016\/j.biomaterials.2018.07.052_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006516","article-title":"Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination","volume":"5","author":"Li","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2018.07.052_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-018-2158-4","article-title":"Personalized cancer vaccines: adjuvants are important, too","author":"Gouttefangeas","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biomaterials.2018.07.052_bib57","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nri2451","article-title":"Harnessing invariant NKT cells in vaccination strategies","volume":"9","author":"Cerundolo","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"13","key":"10.1016\/j.biomaterials.2018.07.052_bib58","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.vaccine.2008.01.030","article-title":"TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses","volume":"26","author":"Schlosser","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.biomaterials.2018.07.052_bib59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nmat2960","article-title":"Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses","volume":"10","author":"Moon","year":"2011","journal-title":"Nat. Mater."},{"issue":"7549","key":"10.1016\/j.biomaterials.2018.07.052_bib60","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2018.07.052_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nm.3773","article-title":"High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma","volume":"21","author":"Linnemann","year":"2015","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.biomaterials.2018.07.052_bib62","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J. Clin. Invest."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014296121830543X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014296121830543X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T16:36:12Z","timestamp":1758904572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014296121830543X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":62,"alternative-id":["S014296121830543X"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.07.052","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2018.07.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}